Latest Headlines

Latest Headlines

BioInvent, BiondVax pocket $9.5M each in separate stock sales

BioInvent and BiondVax Pharmaceuticals have wrapped up their respective fundraising initiatives. Sweden's BioInvent pulled in $9.5 million to fuel the advance of its oncology pipeline, while Israel's BiondVax bagged a similar amount to continue work on its universal flu vaccine.

BioInvent axes 20 jobs and tightens focus on cancer drugs

After a round a layoffs this summer, Lund, Sweden-based biotech BioInvent International has revealed further staff cutbacks as it hones in on cancer drug R&D.

BioInvent plunges (again) as another trial ends in disaster

The news at Sweden's BioInvent is all bad. Today it says that one of the two drugs it planned to shift its focus to failed a Phase IIa trial.

BioInvent forced to reorganize, ax staffers in wake of study failure

Shares at Sweden's BioInvent went into meltdown mode earlier this month when an experimental blood-thinner it was developing in partnership with Thrombogenics failed in a head-to-head study with Xarelto. Today the other foot dropped. BioInvent is reorganizing in the wake of the trial disaster, laying off 21 of its 89 staffers and refocusing on a pair of experimental drugs further down the pipeline.

HGS, BioInvent ink antibody deal

Human Genome Sciences and BioInvent International have inked a deal to discover, develop and commercialize therapeutic monoclonal antibodies that specifically target antigens discovered by HGS.

BioInvent, Daiichi Sankyo sign antibody pact

Sweden's BioInvent International has inked a license and discovery agreement with Japanese drugmaker Daiichi Sankyo to develop therapeutic antibodies against multiple targets. Under the terms of the

Roche signs up for $774M development pact

Roche has forged a $774 million deal to license an early stage cancer drug from Belgium's ThromboGenics and Sweden's BioInvent. In the deal, ThromboGenics gets a whopping $77.4 million upfront